2692 related articles for article (PubMed ID: 795538)
1. Phase I trial of dianhydrogalactitol administered Iv in a weekly schedule.
Vogel CL; Winton EF; Moore MR; Sohner S
Cancer Treat Rep; 1976 Jul; 60(7):895-901. PubMed ID: 795538
[TBL] [Abstract][Full Text] [Related]
2. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.
Perry MC; Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
Cancer Treat Rep; 1976 Sep; 60(9):1247-50. PubMed ID: 797447
[TBL] [Abstract][Full Text] [Related]
3. Phase I evaluation of dianhydrogalactitol (NSC-132313).
Haas CD; Stephens RL; Hollister M; Hoogstraten B
Cancer Treat Rep; 1976 May; 60(5):611-4. PubMed ID: 991150
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of dianhydrogalactitol in metastatic malignant melanoma: a Southwest Oncology Group study.
Thigpen JT; Al-Sarraf M; Hewlett JS
Cancer Treat Rep; 1979 Apr; 63(4):525-8. PubMed ID: 445506
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
Ahmann DL; O'Connell MJ; Bisel HF; Edmonson JH; Hahn RG; Frytak S
Cancer Treat Rep; 1977; 61(1):81-2. PubMed ID: 324622
[No Abstract] [Full Text] [Related]
7. Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.
Ahmann DL; Bisel HF; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S
Cancer Treat Rep; 1976 Nov; 60(11):1681-2. PubMed ID: 1021239
[No Abstract] [Full Text] [Related]
8. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
Pitot HC; McElroy EA; Reid JM; Windebank AJ; Sloan JA; Erlichman C; Bagniewski PG; Walker DL; Rubin J; Goldberg RM; Adjei AA; Ames MM
Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of metoprine in patients with advanced cancer.
Currie VE; Kempin SJ; Young CW
Cancer Treat Rep; 1980; 64(8-9):951-6. PubMed ID: 6969632
[TBL] [Abstract][Full Text] [Related]
10. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
Woodcock TM; Schneider RJ; Young CW
Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol.
Eagan RT; Ames MM; Powis G; Kovach JS
Cancer Treat Rep; 1982 Feb; 66(2):283-7. PubMed ID: 7034934
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
14. Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5'-phosphate using a weekly intravenous regimen.
Schilcher RB; Haas CD; Samson MK; Young JD; Baker LH
Cancer Res; 1986 Jun; 46(6):3147-51. PubMed ID: 3698029
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
[TBL] [Abstract][Full Text] [Related]
16. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
Johnson DH; Paul DM; Hande KR; DeVore R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
[TBL] [Abstract][Full Text] [Related]
18. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
Löffler TM; Freund W; Lipke J; Hausamen TU
Semin Oncol; 1996 Dec; 23(6 Suppl 16):32-4. PubMed ID: 9007118
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.
Khayat D; Lokiec F; Bizzari JP; Weil M; Meeus L; Sellami M; Rouesse J; Banzet P; Jacquillat C
Cancer Res; 1987 Dec; 47(24 Pt 1):6782-5. PubMed ID: 3677107
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
